Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Bruce J. Auerbach"'
Autor:
Hilary A. Feister, Bruce J. Auerbach, Lisa A. Cole, Brian R. Krause, Sotirios K. Karathanasis
Publikováno v:
Journal of Lipid Research, Vol 43, Iss 6, Pp 960-970 (2002)
LCAT is a key enzyme of reverse cholesterol transport that is essential to maintain HDL-mediated lipid transport and cholesterol homeostasis. Alterations in LCAT expression have a profound effect on plasma HDL cholesterol concentrations. Previously L
Externí odkaz:
https://doaj.org/article/2cf0e0ec57c143379d476302f07f5480
Autor:
Charles L. Bisgaier, Arnold D. Essenburg, Blake C. Barnett, Bruce J. Auerbach, Sabine Haubenwallner, Todd Leff, Andrew D. White, Paul Creger, Michael E. Pape, Thomas J. Rea, Roger S. Newton
Publikováno v:
Journal of Lipid Research, Vol 39, Iss 1, Pp 17-30 (1998)
In the current studies we describe the effects of PD 72953 and related compounds on lipoprotein levels in chowfed male rats. After 2 weeks, 10 mg/kg of PD 72953 daily was as effective as 100 mg/kg gemfibrozil for elevating HDL-cholesterol. At 100 mg/
Externí odkaz:
https://doaj.org/article/c311ea301bc5471db5bad401d9635744
Autor:
Brian R. Krause, Alan T. Remaley, Robert D. Shamburek, Lita A. Freeman, Marcelo Amar, Reynold Homan, Bruce J. Auerbach, Rebecca Bakker-Arkema
Publikováno v:
Journal of Clinical Lipidology. 10:356-367
Background Humans with familial lecithin:cholesterol acyltransferase (LCAT) deficiency (FLD) have extremely low or undetectable high-density lipoprotein cholesterol (HDL-C) levels and by early adulthood develop many manifestations of the disorder, in
Autor:
Steve J. Adelman, Anna Wolska, Marcelo Amar, Robert D. Shamburek, Reynold Homan, Alexandra M. Shamburek, Bruce J. Auerbach, Heidi L. Collins, Rebecca Bakker-Arkema, Brian R. Krause, Alan T. Remaley, Lita A. Freeman, Maureen Sampson
Rationale: Low high-density lipoprotein-cholesterol (HDL-C) in patients with coronary heart disease (CHD) may be caused by rate-limiting amounts of lecithin:cholesterol acyltransferase (LCAT). Raising LCAT may be beneficial for CHD, as well as for fa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2972e5dfa052d1f6b68f7b2cf3674ab8
https://europepmc.org/articles/PMC4740220/
https://europepmc.org/articles/PMC4740220/
Autor:
Charles L. Bisgaier, Bruce J. Auerbach
Publikováno v:
Circulation. 132
Background: Gemcabene (Gem) is a late-stage Phase 2 clinical candidate being evaluated for the reduction of low-density lipoprotein cholesterol (LDL-C) in homozygous familial hypercholesterolemia (HoFH) patients. Combination therapy includes statins
Autor:
Xavier Rousset, Bruce J. Auerbach, Gyorgy Csako, Robert D. Shamburek, Brian R. Krause, Reyn Homan, Boris L. Vaisman, Alan T. Remaley, John A. Stonik
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 335:140-148
Lecithin cholesterol acyl transferase (LCAT) deficiency is associated with low high-density lipoprotein (HDL) and the presence of an abnormal lipoprotein called lipoprotein X (Lp-X) that contributes to end-stage renal disease. We examined the possibi
Publikováno v:
Current Medicinal Chemistry-Immunology, Endocrine & Metabolic Agents. 1:39-46
Autor:
Miriam A. Ansong, Bruce J. Auerbach, Roger S. Newton, William Cain, Charles L. Bisgaier, Uday Saxena
Publikováno v:
Atherosclerosis. 142:89-96
The trapping of apolipoprotein (apo)B containing lipoproteins within the arterial subendothelial matrix (ECM) is an early event in atherosclerosis. When lipoprotein lipase, a constituent of the ECM, is prebound to ECM both LDL and oxidized LDL bindin
Autor:
Bruce J. Auerbach, Michael E. Pape, Blake C. Barnett, Todd Leff, Thomas J. Rea, A. D. Essenburg, Andrew D. White, Paul Leroy Creger, Roger S. Newton, Sabine Haubenwallner, Charles L. Bisgaier
Publikováno v:
Journal of Lipid Research, Vol 39, Iss 1, Pp 17-30 (1998)
In the current studies we describe the effects of PD 72953 and related compounds on lipoprotein levels in chowfed male rats. After 2 weeks, 10 mg/kg of PD 72953 daily was as effective as 100 mg/kg gemfibrozil for elevating HDL-cholesterol. At 100 mg/
Autor:
Catherine S. Sekerke, Charles L. Bisgaier, A. D. Essenburg, M E Pape, A Gee, Roger S. Newton, S Wölle, Bruce J. Auerbach
Publikováno v:
Journal of Lipid Research, Vol 38, Iss 12, Pp 2502-2515 (1997)
Low density lipoprotein (LDL) reduction independent of LDL receptor regulation was investigated using HMG-CoA reductase inhibitors in LDL receptor-deficient mice. In males, LDL cholesterol dose-dependently decreased with atorvastatin treatment after